Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgement of Commercial Support

This activity is supported by educational grants from Advanced Accelerator Applications USA, Inc.; AstraZeneca; Bristol Myers Squibb; Daiichi Sankyo, Inc.; Exelixis, Inc.; Ipsen Biopharmaceuticals, Inc.; Lilly; Pfizer Inc.; Sumitomo Dainippon Pharma Oncology, Inc; Taiho Oncology, Inc; and Varian Medical Systems.

For further information concerning Lilly grant funding visit www.lillygrantoffice.com.

Community Practice Connections™ 17th Annual Meeting of the International Society of Gastrointestinal Oncology

Release Date: December 14, 2020
Expiration Date: December 14, 2021

Activity Overview

The overall disease burden of gastrointestinal malignancies remains a key concern for oncology. However, numerous advances in molecular characterization, management, and development of novel therapies have contributed to significant advances in outcomes for patients. In particular, new targeted and immunological treatment options are now available for subgroups of tumors.

This Community Practice Connection™ program provides an in-depth review of some of the key highlights from the 17th Annual Meeting of the International Society of Gastrointestinal Oncology, held in October 2020. This unique and engaging multimedia activity is ideal for the community-based clinician and focuses on the practical aspects managing patients with GI cancers, putting recent clinical trial data into clinical context. The program is designed for those who did not attend the live meeting and to help reinforce learnings for those who did.

Acknowledgement of Commercial Support

This activity is supported by educational grants from Advanced Accelerator Applications USA, Inc.; AstraZeneca; Bristol Myers Squibb; Daiichi Sankyo, Inc.; Exelixis, Inc.; Ipsen Biopharmaceuticals, Inc.; Lilly; Pfizer Inc.; Sumitomo Dainippon Pharma Oncology, Inc; Taiho Oncology, Inc; and Varian Medical Systems.

For further information concerning Lilly grant funding visit www.lillygrantoffice.com.

 

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.


Target Audience

This educational activity is directed toward oncologists and practitioners of oncology subspecialties, along with surgeons, radiologists, general scientists, young investigators, nurses, and pharmacists with an interest in gastrointestinal (GI) oncology. Other health care professionals interested in the treatment of these malignancies are also invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Describe current standards of care for treatment of GI malignancies
  • Discuss recent advances and innovations in the management of GI malignancies
  • Analyze clinical trial data that may impact treatment decision-making in GI oncology
  • Implement a multimodal approach to the treatment of GI malignancies, including gastric, pancreatic, and colorectal cancers, hepatocellular carcinoma, and cholangiocarcinoma

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Faculty

Tanios Bekaii-Saab, MD, FACP
Tanios Bekaii-Saab, MD, FACP
Professor
Mayo Clinic College of Medicine and Science
Program Leader, Gastrointestinal Cancer
Mayo Clinic Cancer Center
Consultant
Mayo Clinic AZ, USA
Consortium Chair
ACCRU
Phoenix, AZ

Disclosures: Grant/Research Support: Research Funding (to institution): AbGenomics (now AltruBio), Agios Pharmaceuticals, Amgen, Array Biopharma, Arrys Therapeutics, Bayer, Boston Biomedical, Bristol Myers Squibb, Merck & Co, Celgene, Clovis Oncology, Eli Lilly and Company, Genentech, Incyte Corporation, Ipsen, Merus, Mirati Therapeutics, Novartis, Pfizer, Seattle Genetics. Consultant: Consulting (to institution): Array Biopharma, Bayer, Genentech, Incyte Corporation, Ipsen, Merck & Co, Pfizer, Seattle Genetics. Consulting (to self): Boehringer Ingelheim, Celularity, Daiichi Sankyo, Eisai, Exact Science, Janssen Pharmaceuticals, Natera, TreosBio, Sobi. Other: IDMC/DSMB (to self): 1Globe, AstraZeneca, Eli Lilly and Company, Exelixis, Pancreatic Cancer Action Network. Scientific Advisory Board: Immuneering Corporation, Imugene, Sun Pharma. Inventions/Patents: WO/2018/183488 and WO/2019/055687

Andrea Cercek, MD
Andrea Cercek, MD
Medical Oncologist
Memorial Sloan Kettering Cancer Center
New York, NY

Disclosures: Grant/Research Support: Rgenix, Seattle Genetics, Tesaro/GlaxoSmithKline. Consultant: Array Biopharma, Bayer.

Yelena Y. Janjigian MD
Yelena Y. Janjigian MD
Chief, Gastrointestinal Oncology Service
Memorial Sloan Kettering Cancer Center
New York, NY

Disclosures: Grant/Research Support: Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Genentech/Roche, Eli Lilly and Company, Merck. Consultant: Bayer, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly and Company, Imugene, Merck & Co., Merck Serono, Merck Sharpe and Dohme Corp., Pfizer. AstraZeneca, Jounce Therapeutics, ONO Pharma, Rgenix, Seattle Genetics, Zymeworks Inc. Shareholder: Rgenix (stock options)

Milind Javle, MD
Milind Javle, MD
Professor, Department of Gastrointestinal Medical Oncology
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX

Disclosures: Grant/Research Support: Agios Pharmaceuticals, AstraZeneca, Eli Lilly and Company, Incyte Corporation, Novartis, QED Bioscience. Consultant: Agios Pharmaceuticals, AstraZeneca, Eli Lilly and Company, Incyte Corporation, Novartis, QED Bioscience, Taiho Pharmaceutical Group.

M. Bassam Sonbol, MD
M. Bassam Sonbol, MD
Assistant Professor of Medicine
Gastrointestinal Oncology program
Mayo Clinic, Arizona

Disclosures: M. Bassam Sonbol, MDhas no relevant financial relationships with commercial interests.

The staff of Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.


Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
   1234
567891011
12131415161718
19202122232425
262728293031
Filter By